SG11201808710UA - Novel immunogenic cd1d binding peptides - Google Patents
Novel immunogenic cd1d binding peptidesInfo
- Publication number
- SG11201808710UA SG11201808710UA SG11201808710UA SG11201808710UA SG11201808710UA SG 11201808710U A SG11201808710U A SG 11201808710UA SG 11201808710U A SG11201808710U A SG 11201808710UA SG 11201808710U A SG11201808710U A SG 11201808710UA SG 11201808710U A SG11201808710U A SG 11201808710UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- peptides
- pct
- rule
- cd1d binding
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 abstract 1
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000016139 endolymphatic sac tumor Diseases 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000581 natural killer T-cell Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- -1 tryptophan amino acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI 010111110101111 0 111 01111101011101011111011111011 OEN Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/182528 Al 26 October 2017 (26.10.2017) WIPO I PCT (51) International Patent Classification: A61K 39/00 (2006.01) C07K 14/74 (2006.01) (21) International Application Number: PCT/EP2017/059302 (22) International Filing Date: 19 April 2017 (19.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16166054.3 19 April 2016 (19.04.2016) EP (71) Applicant: IMCYSE SA [BE/BE]; GIGA B34 - Avenue de l'Hopital 1, 4000 Liege (BE). (72) Inventor: VANDER ELST, Luc; 48 rue du Village, 6230 Obaix (BE). (74) Agent: DE CLERCQ & PARTNERS; Edgard Gevaert- dreef 10a, 9830 Sint-Martens-Latem (BE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = _ = — = _ — (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, _ = = = _ _ EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = KM, ML, MR, NE, SN, TD, TG). = — Declarations under Rule 4.17: = — — of inventorship (Rule 4.17(iv)) Published: — — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) \"It - I4 ot ei in ei of (54) Title: NOVEL IMMUNOGENIC CD1D BINDING PEPTIDES 1-1 ---- (57) : The invention relates to isolated immunogenic peptides comprising a CD1d binding peptide, and immediately adjacent IN ,_ 1 or separated from said CD binding peptide, a redox motif sequence which is further flanked by a histidine or tryptophan amino acids. C::::) The invention further relates to these peptides for use as a medicament The invention further relates to methods wherein these peptides N are used for generating NKT cells which are cytolytic against cells presenting the cognate antigen. C
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16166054 | 2016-04-19 | ||
PCT/EP2017/059302 WO2017182528A1 (en) | 2016-04-19 | 2017-04-19 | Novel immunogenic cd1d binding peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808710UA true SG11201808710UA (en) | 2018-11-29 |
Family
ID=56024090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808710UA SG11201808710UA (en) | 2016-04-19 | 2017-04-19 | Novel immunogenic cd1d binding peptides |
Country Status (13)
Country | Link |
---|---|
US (2) | US11485768B2 (en) |
EP (1) | EP3445390A1 (en) |
JP (2) | JP7320947B2 (en) |
KR (3) | KR20180134935A (en) |
CN (1) | CN109069605B (en) |
AU (2) | AU2017252192C1 (en) |
BR (1) | BR112018071466A2 (en) |
CA (1) | CA3019266A1 (en) |
IL (1) | IL262286B2 (en) |
RU (1) | RU2018136760A (en) |
SG (1) | SG11201808710UA (en) |
WO (1) | WO2017182528A1 (en) |
ZA (1) | ZA201806860B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9249202B2 (en) | 2006-08-11 | 2016-02-02 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in immune disorders |
EP2719396B1 (en) | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
EP3939606A3 (en) | 2015-09-25 | 2022-04-20 | ImCyse SA | Improved methods and compounds for eliminating immune responses to therapeutic agents |
US20210401976A1 (en) * | 2018-11-12 | 2021-12-30 | Imcyse Sa | Immunogenic peptides with improved oxidoreductase motifs |
EP3969039A1 (en) | 2019-05-16 | 2022-03-23 | Imcyse SA | Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine |
TW202208413A (en) | 2020-05-06 | 2022-03-01 | 比利時商伊賽斯公司 | Peptides and methods for the treatment of multiple sclerosis |
JP2023525276A (en) * | 2020-05-06 | 2023-06-15 | アンシス・エスア | Immunogenic peptides with extended oxidoreductase motifs |
CA3182369A1 (en) | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
AR126654A1 (en) | 2021-06-29 | 2023-11-01 | Imcyse Sa | PEPTIDES AND METHODS FOR THE TREATMENT OF OPTICAL NEUROMYELITIS |
TW202340224A (en) * | 2021-11-10 | 2023-10-16 | 美商帝斯肯醫療公司 | Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof |
CN114196629B (en) * | 2021-12-23 | 2024-02-27 | 珠海贝索细胞科学技术有限公司 | Reagent for efficiently culturing NKT cells, application thereof and NKT cell culturing method |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
WO1985004103A1 (en) | 1984-03-09 | 1985-09-26 | Scripps Clinic And Research Foundation | Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants |
US4886782A (en) | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
US5433948A (en) | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
ATE238065T1 (en) | 1990-09-27 | 2003-05-15 | Tripep Ab | PEPTIDES FOR USE IN VACCINATION AND STIMULATION OF ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS |
KR100260342B1 (en) | 1991-10-16 | 2000-07-01 | 스타세이 엘. 첸링 | T cell epitopes of the major allergens from dermatophagoides |
US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
US5589582A (en) | 1992-10-27 | 1996-12-31 | Biotransplant, Inc. | Polynucleotides en coding porcine cytokines |
US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
US5824315A (en) | 1993-10-25 | 1998-10-20 | Anergen, Inc. | Binding affinity of antigenic peptides for MHC molecules |
US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
US6399383B1 (en) | 1997-10-28 | 2002-06-04 | Maxygen, Inc. | Human papilloma virus vectors |
NO315238B1 (en) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptides derived from reading frame shift mutations in the TBF <beta> II or BAX gene, and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids, and virus vector-encompassing such nucleic acid |
US20030152581A1 (en) | 1998-07-30 | 2003-08-14 | Jean-Marie Saint-Remy | Compound and method for the prevention and/or the treatment of allergy |
AR020102A1 (en) | 1998-07-30 | 2002-04-10 | Ucb Sa | COMPOSITE FOR THE PREVENTION AND / OR TREATMENT OF ALLERGY; PHARMACEUTICAL COMPOSITION, COSMETIC COMPOSITION, COMPOSITION IN THE FORM OF DRINK, FOOD AND / OR FOOD FOR DOMESTIC ANIMALS THAT INCLUDES IT AND USE OF SUCH COMPOUND OR SUCH PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A FOOD |
CN1230444C (en) | 1998-11-16 | 2005-12-07 | 德克萨斯州立大学董事会 | HIV-specfic T-cell induction |
GB0006437D0 (en) | 2000-03-17 | 2000-05-10 | Leuven Res & Dev Vzw | Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens |
EP2258852A1 (en) | 2000-04-28 | 2010-12-08 | Novozymes A/S | Lipolytic enzyme variant |
JP2004501648A (en) | 2000-06-26 | 2004-01-22 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Triple fusion proteins containing ubiquitin fused between thioredoxin and a polypeptide of interest |
US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
ATE323151T1 (en) | 2001-05-30 | 2006-04-15 | Fond Telethon | EX-VIVO ISOLATED CD25+CD4+ T CELLS WITH IMMUNOSUPRESSIVE ACTIVITY AND THEIR APPLICATIONS |
DK1432738T3 (en) | 2001-10-03 | 2009-05-25 | Unilever Nv | Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents as well as compositions containing the fusion proteins |
US20100183652A1 (en) | 2002-02-21 | 2010-07-22 | Mark Page | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS |
AU2003215395A1 (en) | 2002-02-21 | 2003-09-09 | Apovia, Inc. | STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS |
JP4406607B2 (en) | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | Peptide and pharmaceutical containing the same |
EP2261249B1 (en) | 2002-09-12 | 2015-02-11 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
EP1556072B1 (en) * | 2002-09-17 | 2010-05-19 | Antigen Express, Inc. | Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES |
JP2004147649A (en) | 2002-10-11 | 2004-05-27 | Kumamoto Technology & Industry Foundation | Antigen to head and neck cancer |
EP1609107A4 (en) | 2003-03-28 | 2006-08-30 | Idm Pharma Inc | Methods of identifying optimal variants of peptide epitopes |
US7651855B2 (en) | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
GB0324265D0 (en) | 2003-10-16 | 2003-11-19 | Medical Res Council | Peptide |
WO2005042575A2 (en) | 2003-10-30 | 2005-05-12 | Pharmexa A/S | Method for down-regulation of vegf |
JP2008044848A (en) | 2004-11-30 | 2008-02-28 | Univ Kurume | Hla-a24-restricted tumor antigen peptide |
US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
FR2898275B1 (en) | 2006-03-10 | 2012-12-14 | Genethon | CD4 + CD25 + REGULATORY T CELLS SPECIFIC FOR HEMATOPOIETIC CELL TRANSPLANT AND IMMUNE TOLERANCE |
WO2007135684A2 (en) | 2006-05-22 | 2007-11-29 | Hadasit Medical Research Services & Development Limited | Method of treatment of anti-cd4 autoimmunity |
US9249202B2 (en) | 2006-08-11 | 2016-02-02 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in immune disorders |
WO2008145400A2 (en) | 2007-05-31 | 2008-12-04 | Medigene Ag | Mutated structural protein of a parvovirus |
US8546137B2 (en) | 2007-09-27 | 2013-10-01 | The Board Of Trustees Of The University Of Arkansas | Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor |
EP2245059B1 (en) | 2008-02-14 | 2017-09-20 | Life Sciences Research Partners VZW | Cd4+ t-cells with cytolytic properties |
PL2249864T3 (en) | 2008-02-14 | 2016-11-30 | Strategies to prevent and/or treat immune responses to soluble allofactors | |
EP2719396B1 (en) | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
CA2715488C (en) | 2008-02-14 | 2019-09-24 | Life Sciences Research Partners Vzw | Immunogenic control of tumours and tumour cells |
CA2715517C (en) | 2008-02-14 | 2018-07-24 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in preventing or treating allograft rejection |
CA2715484C (en) | 2008-02-14 | 2017-04-11 | Life Sciences Research Partners Vzw | Suppression of immune responses to viral vectors |
WO2009106073A2 (en) | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
KR101022649B1 (en) | 2008-08-07 | 2011-03-22 | 삼성모바일디스플레이주식회사 | Heterocyclic compound and an organic light emitting device comprising the same |
WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
US8647879B2 (en) * | 2009-08-14 | 2014-02-11 | Polytechnic Institute Of Nyu | Peptide probe for rapid and specific detection of β-amyloid aggregation |
EP2552476B1 (en) | 2010-03-29 | 2016-12-07 | Centre National De La Recherche Scientifique - Cnrs | Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof |
CA2818536C (en) * | 2010-11-25 | 2020-04-28 | Imnate Sarl | Modulation of antigen immunogenicity by addition of epitopes recognized by nkt cells |
ES2924027T3 (en) | 2010-11-25 | 2022-10-04 | Imcyse Sa | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination |
GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
AU2013220079B2 (en) | 2012-02-15 | 2017-10-05 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
CA2871541A1 (en) * | 2012-04-30 | 2013-11-07 | Imcyse Sa | Methods for induction of antigen-specific regulatory t cells |
US9603948B2 (en) * | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
GB201319160D0 (en) | 2013-10-30 | 2013-12-11 | Imcyse Sa | Methods for induction of antigen-specific regulatory t cells |
GB201418433D0 (en) * | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
EP3939606A3 (en) | 2015-09-25 | 2022-04-20 | ImCyse SA | Improved methods and compounds for eliminating immune responses to therapeutic agents |
-
2017
- 2017-04-19 KR KR1020187031509A patent/KR20180134935A/en not_active Application Discontinuation
- 2017-04-19 CA CA3019266A patent/CA3019266A1/en active Pending
- 2017-04-19 SG SG11201808710UA patent/SG11201808710UA/en unknown
- 2017-04-19 IL IL262286A patent/IL262286B2/en unknown
- 2017-04-19 KR KR1020247002453A patent/KR20240015731A/en active Application Filing
- 2017-04-19 BR BR112018071466-6A patent/BR112018071466A2/en unknown
- 2017-04-19 WO PCT/EP2017/059302 patent/WO2017182528A1/en active Application Filing
- 2017-04-19 CN CN201780024518.0A patent/CN109069605B/en active Active
- 2017-04-19 JP JP2018555682A patent/JP7320947B2/en active Active
- 2017-04-19 EP EP17721070.5A patent/EP3445390A1/en active Pending
- 2017-04-19 US US16/091,549 patent/US11485768B2/en active Active
- 2017-04-19 KR KR1020227031956A patent/KR20220132023A/en active Application Filing
- 2017-04-19 RU RU2018136760A patent/RU2018136760A/en not_active Application Discontinuation
- 2017-04-19 AU AU2017252192A patent/AU2017252192C1/en active Active
-
2018
- 2018-10-15 ZA ZA2018/06860A patent/ZA201806860B/en unknown
-
2021
- 2021-12-10 JP JP2021200876A patent/JP2022022423A/en active Pending
-
2022
- 2022-05-27 AU AU2022203627A patent/AU2022203627A1/en not_active Abandoned
- 2022-09-23 US US17/934,607 patent/US20230265156A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11485768B2 (en) | 2022-11-01 |
CA3019266A1 (en) | 2017-10-26 |
AU2017252192A1 (en) | 2018-10-18 |
IL262286B2 (en) | 2023-12-01 |
ZA201806860B (en) | 2021-05-26 |
AU2022203627A1 (en) | 2022-06-16 |
IL262286B1 (en) | 2023-08-01 |
RU2018136760A3 (en) | 2020-05-27 |
BR112018071466A2 (en) | 2019-03-19 |
KR20220132023A (en) | 2022-09-29 |
AU2017252192C1 (en) | 2023-06-08 |
KR20240015731A (en) | 2024-02-05 |
AU2017252192B2 (en) | 2022-03-03 |
RU2018136760A (en) | 2020-05-19 |
CN109069605A (en) | 2018-12-21 |
JP2022022423A (en) | 2022-02-03 |
CN109069605B (en) | 2022-11-29 |
US20230265156A1 (en) | 2023-08-24 |
IL262286A (en) | 2018-11-29 |
WO2017182528A1 (en) | 2017-10-26 |
US20190106477A1 (en) | 2019-04-11 |
KR20180134935A (en) | 2018-12-19 |
JP2019514895A (en) | 2019-06-06 |
EP3445390A1 (en) | 2019-02-27 |
JP7320947B2 (en) | 2023-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201807868VA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201806538WA (en) | Engineered antigen presenting cells and uses thereof | |
SG11201807472TA (en) | Amanitin conjugates | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201808108XA (en) | Synthesis of indazoles | |
SG11201906198PA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201809594WA (en) | Nicotine particles and compositions | |
SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods |